TP53 has been recently evaluated in a multicenter cohort of 349 patients with myelofibrosis, 13% (49) of whom were TP53-mutated, with a median variant allele frequency (VAF) of 50% [52]. This evidence concerns the gene TP53 and myelofibrosis.